Why the study?
Does the addition of Tongxinluo Capsules to standard DAPT reduce PRU and hsCRP levels in ACS patients with high on-treatment platelet reactivity undergoing PCI?
Does the addition of Tongxinluo Capsules to standard DAPT reduce PRU and hsCRP levels in ACS patients with high on-treatment platelet reactivity undergoing PCI?
Tongxinluo Capsules added to standard DAPT reduce platelet reactivity and inflammation in ACS patients with high on-treatment platelet reactivity undergoing PCI.
Answers are grounded in this paper and cite their sources.
May warrant adjunctive use in high on-treatment reactivity ACS-PCI; extends RCT evidence to heterozygous LOF subgroups.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: